blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2983722

EP2983722 - MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.10.2019
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  09.11.2018
FormerGrant of patent is intended
Status updated on  18.07.2018
FormerExamination is in progress
Status updated on  25.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
BicycleRD Limited
B900
Babraham Research Campus
Cambridge
CB22 3AT / GB
[2018/10]
Former [2016/07]For all designated states
Bicycle Therapeutics Limited
Meditrina
Babraham Research Campus
Cambridge CB22 3AT / GB
Inventor(s)01 / TEUFEL, Daniel Paul
c/o BicycleTx Limited
B900
Babraham Research Campus
Cambridge CB22 3AT / GB
02 / STACE, Catherine
c/o BicycleTx Limited
B900
Babraham Research Campus
Cambridge CB22 3AT / GB
03 / WALKER, Edward
c/o BicycleTx Limited
B900
Babraham Research Campus
Cambridge CB22 3AT / GB
04 / TITE, John
c/o BicycleTx Limited
B900
Babraham Research Campus
Cambridge CB22 3AT / GB
 [2018/50]
Former [2016/07]01 / TEUFEL, Daniel Paul
Bicycle Therapeutics Limited
Itzlings 27
88145 Hergatz / DE
02 / STACE, Catherine
Bicycle Therapeutics Limited
Meditrina
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT / GB
03 / WALKER, Edward
Bicycle Therapeutics Limited
Meditrina
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT / GB
04 / TITE, John
Bicycle Therapeutics Limited
Meditrina
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT / GB
Representative(s)Gibson, Mark
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[N/P]
Former [2016/07]Gibson, Mark
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
Application number, filing date14730083.411.04.2014
[2016/07]
WO2014EP57440
Priority number, dateGB2013000662311.04.2013         Original published format: GB 201306623
[2016/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014167122
Date:16.10.2014
Language:EN
[2014/42]
Type: A1 Application with search report 
No.:EP2983722
Date:17.02.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 16.10.2014 takes the place of the publication of the European patent application.
[2016/07]
Type: B1 Patent specification 
No.:EP2983722
Date:12.12.2018
Language:EN
[2018/50]
Search report(s)International search report - published on:EP16.10.2014
ClassificationIPC:C12N9/64, C07K7/06, C07K7/08, C07K7/54
[2018/27]
CPC:
C12N9/6445 (EP,RU,US); C07K7/06 (RU,US); C07K7/08 (RU,US);
A61P11/02 (EP); A61P17/00 (EP); A61P17/04 (EP);
A61P27/02 (EP,US); A61P27/16 (EP); A61P29/00 (EP);
A61P31/00 (EP); A61P35/00 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P9/00 (EP);
C07K7/50 (US); C07K7/54 (US) (-)
Former IPC [2016/07]A61K47/48
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/07]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MODULATION EINER STRUKTURIERTEN POLYPEPTIDSPEZIFITÄT[2016/07]
English:MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY[2016/07]
French:MODULATION DE LA SPÉCIFICITÉ POLYPEPTIDIQUE STRUCTURÉE[2016/07]
Entry into regional phase29.10.2015National basic fee paid 
29.10.2015Designation fee(s) paid 
29.10.2015Examination fee paid 
Examination procedure29.10.2015Examination requested  [2016/07]
22.06.2016Amendment by applicant (claims and/or description)
23.11.2016Despatch of a communication from the examining division (Time limit: M06)
31.05.2017Reply to a communication from the examining division
26.09.2017Despatch of a communication from the examining division (Time limit: M04)
02.02.2018Reply to a communication from the examining division
19.07.2018Communication of intention to grant the patent
01.11.2018Fee for grant paid
01.11.2018Fee for publishing/printing paid
01.11.2018Receipt of the translation of the claim(s)
Opposition(s)13.09.2019No opposition filed within time limit [2019/47]
Fees paidRenewal fee
18.04.2016Renewal fee patent year 03
20.04.2017Renewal fee patent year 04
20.04.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.04.2014
AL12.12.2018
CY12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
MC12.12.2018
MK12.12.2018
MT12.12.2018
RO12.12.2018
RS12.12.2018
SI12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
LU11.04.2019
IS12.04.2019
[2022/31]
Former [2021/34]HU11.04.2014
AL12.12.2018
CY12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
MC12.12.2018
MT12.12.2018
RO12.12.2018
RS12.12.2018
SI12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
LU11.04.2019
IS12.04.2019
Former [2021/32]HU11.04.2014
AL12.12.2018
CY12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
MC12.12.2018
RO12.12.2018
RS12.12.2018
SI12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
LU11.04.2019
IS12.04.2019
Former [2021/26]AL12.12.2018
CY12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
MC12.12.2018
RO12.12.2018
RS12.12.2018
SI12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
LU11.04.2019
IS12.04.2019
Former [2020/04]AL12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
MC12.12.2018
RO12.12.2018
RS12.12.2018
SI12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
LU11.04.2019
IS12.04.2019
Former [2020/02]AL12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
MC12.12.2018
RO12.12.2018
RS12.12.2018
SI12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
IS12.04.2019
Former [2019/50]AL12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
RO12.12.2018
RS12.12.2018
SI12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
IS12.04.2019
Former [2019/39]AL12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
RO12.12.2018
RS12.12.2018
SK12.12.2018
SM12.12.2018
BG12.03.2019
IS12.04.2019
Former [2019/37]AL12.12.2018
CZ12.12.2018
EE12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
RO12.12.2018
RS12.12.2018
SM12.12.2018
BG12.03.2019
Former [2019/35]AL12.12.2018
CZ12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
RS12.12.2018
BG12.03.2019
Former [2019/26]AL12.12.2018
HR12.12.2018
LT12.12.2018
LV12.12.2018
RS12.12.2018
BG12.03.2019
Former [2019/25]HR12.12.2018
LT12.12.2018
LV12.12.2018
RS12.12.2018
BG12.03.2019
Former [2019/23]HR12.12.2018
LT12.12.2018
LV12.12.2018
BG12.03.2019
Former [2019/22]LT12.12.2018
BG12.03.2019
Former [2019/20]LT12.12.2018
Cited inby applicant  DRIGGERS ET AL., NAT REV DRUG DISCOV, vol. 7, no. 7, 2008, pages 608 - 24
   WU, B. ET AL., SCIENCE, vol. 330, no. 6007, pages 1066 - 71
   XIONG, J. P. ET AL., SCIENCE, vol. 296, no. 5565, 2002, pages 151 - 5
   ZHAO, G. ET AL., J STRUCT BIOL, vol. 160, no. 1, 2007, pages 1 - 10
   CHERNEY, R. J. ET AL., J MED CHEM, vol. 41, no. 11, 1998, pages 1749 - 51
   KEMP, D. S.; MCNAMARA, P. E., J. ORG. CHEM, 1985
   HEINIS ET AL., NAT CHEM BIOL, vol. 5, no. 7, 2009, pages 502 - 7
   TIMMERMAN, P. ET AL., CHEMBIOCHEM, 2005
   CHEN; HARRISON: "Cell-penetrating peptides in drug development: enabling intracellular targets", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 35, 2007, pages 821
   GUPTA ET AL.: "Intracellular delivery of large molecules and small peptides by cell penetrating peptides", ADVANCED DRUG DISCOVERY REVIEWS, vol. 57, 2004, pages 9637
   DEROSSI ET AL.: "The third helix of the Antennapedia homeodomain translocates through biological membranes", J BIOL. CHEM., vol. 269, 1994, pages 10444
   OEHLKE ET AL.: "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically", BIOCHIM BIOPHYS ACTS, vol. 1414, 1998, pages 127, XP000972010, DOI: doi:10.1016/S0005-2736(98)00161-8

DOI:   http://dx.doi.org/10.1016/S0005-2736(98)00161-8
   OKUYAMA ET AL.: "Small- molecule mimics of an a-helix for efficient transport of proteins into cells", NATURE METHODS, vol. 4, 2007, pages 153, XP002504839, DOI: doi:10.1038/NMETH997

DOI:   http://dx.doi.org/10.1038/NMETH997
   ELSON-SCWAB ET AL.: "Guanidinylated Neomcyin Delivers Large Bioactive Cargo into cells through a heparin Sulphate Dependent Pathway", J BIOL CHEM, vol. 282, 2007, pages 13585
   DAWSON PE; MUIR TW; CLARK-LEWIS; KENT, SBH: "ynthesis of Proteins by Native Chemical Ligation", SCIENCE, vol. 266, 1994, pages 776 - 779
   CHANG TK; JACKSON DY; BURNIER JP; WELLS JA: "Subtiligase: a tool for semisynthesis of proteins", PROC NATL ACAD SCI U S A., vol. 91, no. 26, 20 December 1994 (1994-12-20), pages 12544 - 8, XP002280083
   HIKARI A.I. YOSHIHARA; SAMI MAHRUS; JAMES A. WELLS: "Tags for labeling protein N-termini with subtiligase for proteomics", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS TAGS FOR LABELLING PROTEIN N-TERMINI WITH SUBTILIGASE FOR PROTEOMICS, vol. 18, no. 22, 15 November 2008 (2008-11-15), pages 6000 - 6003, XP025627190, DOI: doi:10.1016/j.bmcl.2008.08.044

DOI:   http://dx.doi.org/10.1016/j.bmcl.2008.08.044
   GENTILUCCI ET AL., CURR. PHARMACEUTICAL DESIGN, vol. 16, 2010, pages 3185 - 203
   NESTOR ET AL., CURR. MEDICINAL CHEM, vol. 16, 2009, pages 4399 - 418
   TUGYI ET AL., PNAS, vol. 102, no. 2, 2005, pages 413 - 418
   FIACCO ET AL., CHEMBIOCHEM., vol. 9, no. 14, 2008, pages 2200 - 3
   BIRON ET AL., ANGEW. CHEM. INT. ED., vol. 47, 2008, pages 2595 - 99
   MULLIS; FALOONA, METHODS ENZYMOL., vol. 155, 1987, pages 335
   WINTER ET AL., ANN. REV. IMMUNOLOGY, vol. 12, 1994, pages 433 - 55
   LINDE ET AL.: "Structure- activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides", PEPTIDE SCIENCE, vol. 90, 2008, pages 671 - 682
   HESS ET AL.: "backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administered drug lead for treating obesity", J. MED. CHEM., vol. 51, 2008, pages 1026 - 1034
   JESPERS ET AL., PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 17, no. 10, 2004, pages 709 - 713
   MARKS ET AL., J.MOL.BIOL, vol. 222, pages 581 - 597
   LEFKOVITE; PERNIS: "Immunological Methods", vol. I, 1979, ACADEMIC PRESS
   KNIGHT ET AL., J EXP. MED., vol. 147, 1978, pages 1653
   REINERSTEN ET AL., NEW ENG. J : MED., vol. 299, 1978, pages 515
   LINDSTROM ET AL., ADV. INZN7UNOL., vol. 42, 1988, pages 233
   STUART ET AL., ANN. REV. IMMUNOL., vol. 42, 1984, pages 233
   VAN EDEN ET AL., NATURE, vol. 331, 1988, pages 171
   MARON ET AL., J. EXP. MED., vol. 152, 1980, pages 1115
   KANASAWA ET AL., DIABETOLOGIA, vol. 27, 1984, pages 113
   PATERSON ET AL.: "Textbook of Immunopathology", 1986, GRUNE AND STRATTON, pages: 179 - 213
   MCFARLIN ET AL., SCIENCE, vol. 179, 1973, pages 478
   SATOH ET AL., J ; IMMUNOL., vol. 138, 1987, pages 179
   MACK: "Remington's Pharmaceutical Sciences", 1982
   BARBAS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4457
   HOOGENBOOM; WINTER, R MOL. BIOL., vol. 227, 1992, pages 381
   NISSIM ET AL., EMBO J, vol. 13, 1994, pages 692
   GRIFFITHS ET AL., EMBO J, vol. 13, 1994, pages 3245
   DE KRUIF ET AL., J. MOL. BIOL., vol. 248, 1995, pages 97
   CRAMERI ET AL., NATURE MED., vol. 2, 1996, pages 100
   RIECHMANN ET AL., BIOLTECHNOLOGY, vol. 13, 1995, pages 475
   KATHER ET AL., J MOL BIOL, vol. 354, no. 3, 2005, pages 666 - 78
   BACKLIWAL ET AL., BIOTECHNOL BIOENG, vol. 99, no. 3, 2008, pages 721 - 7
   HEINIS ET AL., NATURE CHEMICAL BIOLOGY, vol. 5, 2009, pages 502 - 507
   RONALD N; ZUCKERMANN; JANICE M. KERR; STEPHEN B. H. KENT; WALTER H. MOOS: "Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 114, no. 26, 1992, pages 10646 - 10647
   SASAKI Y; COY DH.: "Solid phase synthesis of peptides containing the CH2NH peptide bond isostere", PEPTIDES, vol. 8, no. 1, January 1987 (1987-01-01), pages 119 - 21, XP023892570, DOI: doi:10.1016/0196-9781(87)90174-4

DOI:   http://dx.doi.org/10.1016/0196-9781(87)90174-4
   CHATTERJEE ET AL.: "Synthesis of N-methylated cyclic peptides", NATURE PROTOCOLS, vol. 7, no. 3, 2012, pages 432, XP055131862, DOI: doi:10.1038/nprot.2011.450

DOI:   http://dx.doi.org/10.1038/nprot.2011.450
   STURZEBECHER ET AL.: "Novel plasma Kallikrein inhibitors of the benzamidine type", BRAZ J MED BIOL RES., vol. 27, no. 8, 1994, pages 1929 - 34, XP009030092
   TANG ET AL.: "Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma Kallikrein", J.BIOI.CHEM., vol. 280, 2005, pages 41077 - 89, XP055061755, DOI: doi:10.1074/jbc.M506766200

DOI:   http://dx.doi.org/10.1074/jbc.M506766200
   SPERL ET AL.: "4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase", PROC NATL ACAD SCI U S A., vol. 97, no. 10, 2000, pages 5113 - 8, XP002169711, DOI: doi:10.1073/pnas.97.10.5113

DOI:   http://dx.doi.org/10.1073/pnas.97.10.5113
   SCHREIBER ET AL.: "Rapid, electrostatically assisted association of proteins", NATURE STRUCT. BIOL., vol. 3, 1996, pages 427 - 31
   TONIOLO ET AL., BIOPOLYMERS, vol. 33, 1993, pages 1061 - 72
   KARLE ET AL., BIOCHEMISTRY, vol. 29, 1990, pages 6747 - 56
   JOBIN J; BONJOUR JP, AM J PHYSIOL., vol. 248, 1985, pages F734 - 8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.